Navigating the Prognostic Role of Transfusions After CAR-T
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Rejeski K, Wang Y, Hansen D, Iacoboni G, Bachy E, Bansal R
. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024; 8(8):1857-1868.
PMC: 11007437.
DOI: 10.1182/bloodadvances.2023011767.
View
2.
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P
. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023; 142(10):865-877.
DOI: 10.1182/blood.2023020578.
View
3.
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L
. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021; 138(24):2499-2513.
PMC: 8893508.
DOI: 10.1182/blood.2020010543.
View
4.
Juluri K, Wu Q, Voutsinas J, Hou J, Hirayama A, Mullane E
. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2021; 6(7):2055-2068.
PMC: 9006285.
DOI: 10.1182/bloodadvances.2020004142.
View
5.
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T
. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4(15):3776-3787.
PMC: 7422135.
DOI: 10.1182/bloodadvances.2020002509.
View